These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10882574)

  • 21. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
    Laassri M; Lottenbach K; Belshe R; Rennels M; Plotkin S; Chumakov K
    J Infect Dis; 2006 May; 193(10):1344-9. PubMed ID: 16619180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on the neutralization of poliovirus by fecal immunoglobulins. The development of intestinal IgA antibodies following oral poliovirus immunization.
    Keller R; Dwyer JE
    Prog Immunobiol Stand; 1970; 4():316-22. PubMed ID: 4320518
    [No Abstract]   [Full Text] [Related]  

  • 23. Poliovirus vaccine strains detected in stool specimens of immunodeficient children in South Africa.
    Pavlov DN; Van Zyl WB; Kruger M; Blignaut L; Grabow WO; Ehlers MM
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):23-30. PubMed ID: 16290028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
    Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
    Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly.
    Buisman AM; Abbink F; Schepp RM; Sonsma JA; Herremans T; Kimman TG
    J Infect Dis; 2008 Mar; 197(5):698-706. PubMed ID: 18279050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different secretory IgA antibody responses after immunization with inactivated and live poliovirus vaccines.
    Hanson LA; Carlsson B; Jalil F; Lindblad BS; Khan SR; van Wezel AL
    Rev Infect Dis; 1984; 6 Suppl 2():S356-60. PubMed ID: 6740073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mucosal and systemic immunity against poliovirus in mice transgenic for the poliovirus receptor: the poliovirus receptor is necessary for a virus-specific mucosal IgA response.
    Buisman AM; Sonsma JA; Kimman TG; Koopmans MP
    J Infect Dis; 2000 Mar; 181(3):815-23. PubMed ID: 10720499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.
    Ivanov AP; Dragunsky EM; Chumakov KM
    J Infect Dis; 2006 Feb; 193(4):598-600. PubMed ID: 16425140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L
    Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
    Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
    Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines.
    Zhaori G; Sun M; Ogra PL
    J Infect Dis; 1988 Jul; 158(1):160-5. PubMed ID: 2839578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
    Dragunsky EM; Ivanov AP; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2006 Sep; 194(6):804-7. PubMed ID: 16941347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India.
    Grassly NC; Jafari H; Bahl S; Durrani S; Wenger J; Sutter RW; Aylward RB
    J Infect Dis; 2009 Sep; 200(5):794-801. PubMed ID: 19624278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secretory and serum immunoglobulin class-specific antibodies to poliovirus after vaccination.
    Carlsson B; Zaman S; Mellander L; Jalil F; Hanson LA
    J Infect Dis; 1985 Dec; 152(6):1238-44. PubMed ID: 2999260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus.
    Piirainen L; Stenvik M; Roivainen M; Eskola J; Beuvery EC; Hovi T
    Vaccine; 1999 Mar; 17(9-10):1084-90. PubMed ID: 10195618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal immunity induced by inactivated poliovirus vaccine.
    Selvakumar R; John TJ
    Vaccine; 1987 Jun; 5(2):141-4. PubMed ID: 3037815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence and class-specificity of neutralizing antibody response induced by trypsin-cleaved type 3 poliovirus in mice.
    Roivainen M; Piirainen L; Hovi T
    Vaccine; 1993; 11(7):713-7. PubMed ID: 7688171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
    Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
    Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.